Titelbild

Press releases

2021-07-29 – Press release

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

  • Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases
  • Initial clinical data for lead program, TPM203, in pemphigus vulgaris expected this year; second program, TPM502, planned to enter clinic by year end for celiac disease
  • In strong support of Topas’ technology and programs, all existing investors - BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III - participated in the extension

read more …

2020-10-19 – Press release

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

  • Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors
  • Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform
    • Lead program TPM203 in clinical development for pemphigus vulgaris
    • Second program, TPM501, progressing towards clinic for treatment of celiac disease
  • New investors join Supervisory Board; Erich F. Greiner, M.D., becomes Chairman

read more …

2020-10-19 – Press release

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

  • Highly accomplished biotech executive with nearly two decades of industry leadership experience
  • Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform, with lead program TPM203 in clinical development for treatment of pemphigus vulgaris and second program, TPM501, progressing towards clinic for treatment of celiac disease

read more …

2019-12-18 – Press release

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

  • First program from the Topas platform to enter clinical testing
  • TPM203 is one of several proprietary programs being developed by Topas
  • Pemphigus vulgaris is an orphan indication that currently has no cure

read more …

2019-03-20 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

Meet with Topas at following industry Events this spring

  • 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019. March 26-28, 2019, Boston, MA, USA
  • TReg Directed Therapies Summit, May 20-22, 2019, Boston, MA USA
  • 2019 German Biotech Days (Deutsche Biotechnologietage 2019), April 9-10, 2019, Würzburg, Germany
  • 20th Annual Bio€quity Europe, May 20-21, 2019, Barcelona, Spain

read more …